Sirius Investors

CNSP Stock: CNS Pharmaceuticals, Inc. Stock Price, Analysis & Insights

Get live cnsp stock price $6.25, comprehensive CNS Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time cnsp stock data and investment insights.

6.25
0.81%Today
CNSPCNS Pharmaceuticals, Inc. • NASDAQ Capital Market • Healthcare
Market Cap
3.59M
Volume
5.37K
52W High
222.00
52W Low
4.93

Company Overview

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Company Information

CEO
John Michael Climaco
Sector
Healthcare
Industry
Biotechnology
Employees
4

Contact Information

Address
2100 West Loop South
Country
US

Investment Analysis & Insights

Key Investment Highlights

  • Market Position: Healthcare leader with 3.59M market capitalization
  • Trading Volume: 5.37K shares traded today
  • Price Range: 52-week range of $4.93 - $222.00
  • Exchange: Listed on NASDAQ Capital Market

Financial Metrics

P/E Ratio:N/A
EPS:$2131.86
Beta:0.76
Avg Volume:42.22K

Market Analysis for CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. (CNSP) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 3.59M, the company represents a significant player in its market. The stock is currently trading at $6.25 with a positivedaily change of 0.81%.

The company's 4 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of N/A, beta of 0.76, and 52-week price range from $4.93 to $222.00when evaluating investment opportunities.

Why Invest in CNS Pharmaceuticals, Inc.?

Strengths
  • • Established market presence in Healthcare
  • • Strong financial metrics and market position
  • • Listed on major exchange (NASDAQ Capital Market)
  • • Experienced leadership under John Michael Climaco
Investment Considerations
  • • Monitor sector-specific market trends
  • • Track quarterly earnings performance
  • • Consider market volatility and beta
  • • Evaluate long-term growth potential

Related Healthcare Stocks

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.